Biomarkers /
CD276
Overview
CD276 molecule (CD276) is a gene that encodes a protein that is a member of the immunoglobulin superfamily. The protein functions in the T-cell mediated immune response. Missense and silent mutations are observed in cancers such as eye cancer, skin cancer, and stomach cancer.
CD276 is altered in 0.55% of all cancers with colon adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, lung adenocarcinoma, and cutaneous melanoma having the greatest prevalence of alterations [3].
The most common alterations in CD276 are CD276 Amplification (0.09%), CD276 Loss (0.05%), CD276 A105T (0.02%), CD276 M1? (0.02%), and CD276 R92C (0.01%) [3].
Clinical Trials
Significance of CD276 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.